Showing results (131-140 of 245) with videos related to

Sort By:
Pageof 25
Targeted Oncology|May 18, 2016
The Immune Revolution in Gastrointestinal Tumours: Leading the Way or Just Following?Marco Puzzoni, Nicola Silvestris, Francesco Leone, et al.
Annals of Surgical Oncology|January 13, 2012
Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trialMichele Reni, Gianpaolo Balzano, Giuseppe Aprile, et al.
Future Oncology (London, England)|February 17, 2015
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancerLuisa Foltran, Giovanna De Maglio, Nicoletta Pella, et al.
Breast (Edinburgh, Scotland)|April 22, 2018
Controversies in monitoring metastatic breast cancer during systemic treatment. Results of a GIM (Gruppo Italiano Mammella) surveyMarta Bonotto, Debora Basile, Lorenzo Gerratana, et al.
Expert Review of Gastroenterology & Hepatology|October 20, 2021
Cholangiocarcinoma: new perspectives for new horizonsMargherita Rimini, Marco Puzzoni, Federica Pedica, et al.
Cancers|June 12, 2026
Adjuvant Therapy for High-Risk Stage II Cutaneous Melanoma: Insights and Future DirectionsFederico Pravisano, Jacopo Costa, Lorenzo De Marchi, et al.
Clinical Colorectal Cancer|April 2, 2018
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program StudyAlessandro Pastorino, Maria Di Bartolomeo, Evaristo Maiello, et al.
Oncotarget|October 15, 2017
Antiangiogenic agents after first line and sorafenib plus chemoembolization: a systematic reviewAndrea Casadei Gardini, Daniele Santini, Giuseppe Aprile, et al.
Lancet (London, England)|August 24, 2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialYung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, et al.
Journal of the National Cancer Institute|August 29, 2025
Effect of low-dose tamoxifen on benign gynecological and breast conditions in a phase III trial in non-invasive breast cancerAlessio Carbone, Martino Oliva, Matteo Puntoni, et al.
Pageof 25